Provided by Tiger Trade Technology Pte. Ltd.

IGC Pharma

0.2553
-0.0051-1.96%
Post-market: 0.2548-0.0005-0.20%19:53 EDT
Volume:279.21K
Turnover:71.87K
Market Cap:25.22M
PE:-4.26
High:0.2679
Open:0.2670
Low:0.2520
Close:0.2604
52wk High:0.4985
52wk Low:0.2420
Shares:98.80M
Float Shares:87.50M
Volume Ratio:0.76
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0600
EPS(LYR):-0.0931
ROE:-83.34%
ROA:-50.31%
PB:3.12
PE(LYR):-2.74

Loading ...

IGC Pharma Inc - Files Prospectus Related to Offering of 779,997 Shares of Common Stock

THOMSON REUTERS
·
Jan 06

IGC Pharma Secures U.S. Patent for Microdose Cannabinoid Treatment of Stuttering and Tourette's Syndrome

Reuters
·
Dec 19, 2025

IGC Pharma Inc - Increases Authorized Common Stock to 600 Mln Shares - SEC Filing

THOMSON REUTERS
·
Dec 16, 2025

IGC Pharma Quadruples Authorized Common Shares to 600 Million

Reuters
·
Dec 16, 2025

Ascendiant Capital Markets Raises IGC Pharma Price Target to $4.75

Reuters
·
Dec 10, 2025

IGC Pharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 10, 2025

IGC Pharma Reaches 65% Enrollment in Phase 2 CALMA Trial for Alzheimer’s Agitation

Reuters
·
Dec 09, 2025

Press Release: NeoVolta Enters into Definitive Agreements Led by Infinite Grid Capital to Advance 2 GWh U.S. Battery Energy Storage System Manufacturing Initiative

Dow Jones
·
Nov 24, 2025

IGC Pharma Reports Progress Amid Financial Losses

TIPRANKS
·
Nov 18, 2025

IGC Pharma expects ‘continued strong momentum’ into 2H26

TIPRANKS
·
Nov 17, 2025

IGC Pharma Q2 EPS $(0.02), Inline, Sales $191.000K Miss $325.000K Estimate

Benzinga
·
Nov 17, 2025

IGC Pharma Sells Non-Core Facility for $2.7 Million

Reuters
·
Nov 17, 2025

IGC Pharma files to sell 978,235 shares of common stock for holders

TIPRANKS
·
Nov 17, 2025

IGC Pharma Reports Lower Revenue Amid Shift to Alzheimer’s Drug Development

Reuters
·
Nov 15, 2025

IGC Pharma Sells Vancouver Assets to Wellness Essentials

TIPRANKS
·
Nov 14, 2025

IGC Pharma Granted U.S. Patent for Novel Alzheimer's Drug Composition Targeting CNS Disorders

Reuters
·
Nov 13, 2025

IGC Pharma expands Phase 2 CALMA trial to University of South Florida

TIPRANKS
·
Oct 14, 2025

IGC Pharma Inc. Held Annual Meeting of Stockholders

Reuters
·
Oct 14, 2025

IGC Pharma announces in-vitro preclinical data for IGC-1C

TIPRANKS
·
Oct 07, 2025

IGC Pharma Announces Promising Preclinical Results for IGC-1C, a Novel Drug Candidate Targeting Tau Protein in Alzheimer’s Disease

Reuters
·
Oct 07, 2025